Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-7012 in Relapsed or Refractory Cutaneous T-cell Lymphomas
NCT07213882Phase 1Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of DT-7012 in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Dose Limiting Toxicity up to 12 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
DT-7012
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT07213882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213882.